- Bevacizumab toxicity in heavily pretreated recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancers
-
Martin JY, Urban RR, Liao JB, Goff BA
- KMID: 2374249
- J Gynecol Oncol.
- 2016 Sep;27(5):e47.
- doi: 10.3802/jgo.2016.27.e47
OBJECTIVE: Bevacizumab was recently approved by the US Food and Drug Administration for use in recurrent platinum resistant epithelial ovarian cancer (EOC), fallopian tube cancer (FTC), or primary peritoneal cancer... -
- CITED
-
- Close
- SHARE
-
- Close
- ATP-Based Chemotherapy Response Assay in Primary or Recurrent Ovarian and Peritoneal Cancer
-
Lee M, Kim SW, Nam EJ, Cho H, Kim JH, Kim YT, Kim S
- KMID: 2070217
- Yonsei Med J.
- 2014 Nov;55(6):1664-1671.
- doi: 10.3349/ymj.2014.55.6.1664
PURPOSE: To investigate chemosensitivity with an adenosine triphosphate-based chemotherapy response assay in patients with epithelial ovarian or peritoneal cancer according to tumor histology, grade, and disease status. MATERIALS AND METHODS: One... -
- CITED
-
- Close
- SHARE
-
- Close
